2022

Melanoma Patient Subset May Not Face Same Risks Traditionally Associated with the Disease

Scientists using cancer registry data identified a subset of patients with early-stage melanoma with almost no melanoma-related deaths. The study “Prognostic modeling of cutaneous melanoma stage I patients using cancer registry data identifies subsets with very low melanoma mortality,” published in Cancer, may help clinicians determine which patients have a low risk of death from melanoma after removal of the growth, according to the researchers.

Read More

DREAMSeq Trial Clarifies Treatment Sequencing in BRAF V600–Mutant Melanoma

Immunotherapy followed by targeted therapy has emerged as the new standard of care for patients with melanoma with BRAF V600 mutations, according to Andrew L. Pecora, MD, FACP, CPE, who explained that patients tend to live longer when receiving ipilimumab (Yervoy) plus nivolumab (Opdizvo) before receiving dabrafenib (Tafinlar) plus trametinib (Mekinist).

Read More
MRV News
Melanoma News
Archive
Menu